|
Canada-NS-SYDNEY Azienda Directories
|
Azienda News:
- Financial Assistance | IMFINZI® (durvalumab)
IMFINZI is a prescription medicine used to treat adults with a type of lung cancer called NSCLC IMFINZI may be used alone when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy
- Table 3, Cost and Cost-Effectiveness - Durvalumab (Imfinzi . . .
The cost-effectiveness of durvalumab plus gemcitabine and cisplatin in subsequent lines of treatment is unknown The long-term clinical efficacy of durvalumab was uncertain Approximately 68 9% of OS gains from durvalumab predicted in the model occurred through extrapolation beyond the time frame of the TOPAZ-1 trial (maximum duration of follow
- Cost and Imfinzi: Financial assistance options, savings, more
The Imfinzi Co-pay Savings Program is available for Imfinzi For more information and to determine your eligibility for support, call 844-275-2360 or visit the program website
- HCP Support and Resources | IMFINZI® (durvalumab) IMJUDO . . .
Of the 530 patients in the IMFINZI treatment arm and 526 patients in the chemotherapy treatment arm who received neoadjuvant treatment, 1 (0 2%) patient in each treatment arm did not receive surgery due to adverse reactions The adverse reaction that led to cancellation of surgery in the IMFINZI treatment arm was interstitial lung disease
- Financial Assistance for Stage 4 NSCLC | IMFINZI® (durvalumab)
Discover financial assistance programs to help treat your Stage 4 non-small cell lung cancer (NSCLC) with IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) with chemotherapy
|
|